After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m. 

Idhifa is already approved in the US for relapsed or refractory AML patients with IDH2 mutations based on Phase I/II complete responses, but did not meet the overall survival endpoint in the Phase III IDHENTIFY.

Idhifa is approved in the US for relapsed or refractory AML patients with IDH2 mutations based on Phase I/II complete responses but did not meet the overall survival endpoint in the Phase III IDHENTIFY.

The European Commission is in talks to buy vaccines from CureVac and Moderna, amid concerns over “vaccine nationalism” and lack of transparency. Meanwhile the EU health technology assessment network has begun publishing “rolling collaborative reviews” of potential COVID-19 therapies, and two more firms have announced progress with monoclonal antibodies.